Literature DB >> 26873942

Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) guided by implantable loop recorder: multicentre Italian trial based on stroke unit network with paired cardio-arrhythmology units (Italian Neurocardiology Unit Network).

Danilo Toni1, Svetlana Lorenzano2, Stefano Strano3.   

Abstract

RATIONALE: Atrial fibrillation is associated with a high risk of stroke and its prevalence increases in subjects aged ≥65 years. After an ischemic stroke, the use of standard monitoring methods may underestimate the detection rate of atrial fibrillation. Hence, it is very likely that even patients having a first atherothrombotic or lacunar stroke with high burden of vascular risk factors are exposed to increased risk of developing atrial fibrillation in the subsequent years and atrial fibrillation may be the cause underlying possible recurrent strokes AIM AND HYPOTHESIS: The Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) trial has the objective to evaluate the detection of atrial fibrillation or atrial flutter as first diagnosis by implantable loop recorder in patients with first-ever atherothrombotic or lacunar stroke. We hypothesize that the detection will be higher than that observed by using standard cardiac monitoring METHODS AND
DESIGN: SAFFO is a prospective, multicenter, randomized, controlled, open-label trial with blinded assessment of outcome measures. Patients who fulfill inclusion criteria will be randomized to either continuous monitoring using an implantable loop recorder plus standard monitoring (intervention arm) or standard heart rhythm monitoring alone (control arm) with a ratio of 1:1 STUDY OUTCOMES: The primary endpoint is the detection of atrial fibrillation/atrial flutter as first diagnosis in the first 12 months of the study period DISCUSSION: If positive, SAFFO trial could have important clinical implications in terms of changing the standard diagnostic protocol in patients with atherothrombotic and lacunar stroke, and of increasing the shift of secondary prevention treatment from antiplatelet to anticoagulant therapy.
© 2016 World Stroke Organization.

Entities:  

Keywords:  Ischemic stroke; anticoagulants; antithrombotics; atrial fibrillation; implantable loop recorder; stroke subtype

Mesh:

Substances:

Year:  2016        PMID: 26873942     DOI: 10.1177/1747493016631356

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  6 in total

Review 1.  Digital health solutions in the screening of subclinical atrial fibrillation.

Authors:  Sebastian König; Andreas Bollmann; Gerhard Hindricks
Journal:  Herz       Date:  2021-06-04       Impact factor: 1.443

Review 2.  [Event recorder in cryptogenic stroke : Accepted and feasible indications].

Authors:  J Brachmann; M Held
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-11-14

Review 3.  Subcutaneouscardiac Rhythm Monitors: A Comprehensive Review.

Authors:  Gaurav Aggarwal; Saurabh Aggarwal; Venkata Alla; Bharat Narasimhan; Kyungmoo Ryu; Courtney Jeffery; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2021-02-28

Review 4.  Evaluating the benefits of home-based management of atrial fibrillation: current perspectives.

Authors:  Azfar B Sheikh; Jamie R Felzer; Abdullah Bin Munir; Daniel P Morin; Carl J Lavie
Journal:  Pragmat Obs Res       Date:  2016-10-13

Review 5.  The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: advances and uncertainties.

Authors:  Joshua O Cerasuolo; Lauren E Cipriano; Luciano A Sposato
Journal:  Curr Opin Neurol       Date:  2017-02       Impact factor: 5.710

6.  Duration of Implantable Cardiac Monitoring and Detection of Atrial Fibrillation in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Martin Köhrmann; Valeria Caso; Fabienne Perren; Lina Palaiodimou; Spyridon Deftereos; Sotirios Giannopoulos; John Ellul; Christos Krogias; Dimitris Mavridis; Sokratis Triantafyllou; Anne W Alexandrov; Peter D Schellinger; Andrei V Alexandrov
Journal:  J Stroke       Date:  2019-09-30       Impact factor: 6.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.